SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is capturing significant attention due to its upcoming $1 million mainnet perpetuals trading competition and the launch of its V3 perps with multi-collateral support on Ethereum. The community is buzzing about the end of SNX token inflation and the start of buybacks, fueling bullish price speculation and increased trading volume.

Telcoin is a multi-national fintech company  integrating blockchain technology, telecommunications, and digital banking to revolutionize global finance. It aims to provide borderless, instant, and affordable financial services to mobile phone users worldwide. Telcoin offers the Telcoin Wallet, a multi-signature DeFi wallet supporting more than 100 digital assets and remittances to eWallets and bank accounts globally. Telcoin is regulated as a Virtual Asset Service Provider in the EU (Lithuania) and Argentina, a Major Payment Institution in Singapore, and a Money Services Business in the US, Canada, and Australia.   Telcoin is designed to complement telecom, mobile money, and e-wallet partners globally with both traditional fiat and blockchain transaction rails that underpin our fast and affordable digital financial service offerings. Telcoin combines the best parts of the burgeoning DeFi ecosystem with our compliance-focused approach to each market, ensuring that the company takes on a fraction of traditional financial counterparty, execution, and custody risks.  The Telcoin Association is a Swiss non-profit organization domiciled in Lugano, Switzerland and is governed by a decentralized group of Miner Councils that run the various aspects of the Telcoin Platform, including the management of the Telcoin (TEL) token. Read more about the Telcoin Association [here](https://www.telcoin.org).

Telcoin

Telcoin is a hot topic among crypto enthusiasts, who are actively discussing its pioneering role as the first US Digital Asset Bank. The community is eagerly anticipating the launch of its V5 network and eUSD stablecoin, which are seen as pivotal steps in bridging traditional finance with DeFi and driving significant growth.

USDX (Website: usdx.money | Twitter: @StablesLabs) is a synthetic USD stablecoin designed to provide stability without relying on traditional banking infrastructure. Backed by delta-neutral positions across multiple exchanges, USDX seamlessly bridges the gap between DeFi, CeFi, and TradFi. It enables DeFi users to access traditional delta-neutral strategies executed in CeFi platforms. As a crypto-native stablecoin, USDX offers a scalable, censorship-resistant, and highly stable solution for users looking to navigate the world of decentralized finance with confidence.

USDX Stablecoin

USDX Stablecoin is under intense scrutiny after crashing sharply following the Balancer hack, sparking community discussions about the inherent fragility of DeFi stablecoins and broader market concerns over concentrated ownership and regulatory oversight.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

iShares MSCI South Korea ETF (EWY) is trending as it consistently hits new highs, driven by its heavy exposure to the booming semiconductor sector, particularly key players like Samsung and SK Hynix benefiting from surging AI memory demand. The community is actively discussing its significant outperformance against US markets and its appealing valuation in the global landscape.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is trending after the SEC dismissed its lawsuit and a significant partnership with AT&T emerged, solidifying its role in the DePIN sector. Community sentiment is highly polarized, with strong bullish conviction in its real-world utility and institutional interest contrasting with concerns over project management and token economics for miners.

Comtech Telecommunications Corp. engages in the provision of emergency systems and wireless and satellite communications. It operates through Satellite and Space Communications and Allerium segments. The Satellite and Space Communication segment offers satellite ground station technologies, services and system integration that facilitate the transmission of voice, video, and data over GEO, MEO, and LEO satellite constellations, including solid-state and traveling wave tube power amplifiers, modems, VSAT platforms and frequency converters. The Allerium segment provides emergency call routing, location validation, network, policy-based routing rules, logging and security functionality to states and local governments. The company was founded in 1967 and is headquartered in Chandler, AZ.

Comtech Telecommunications Corp.

Comtech Telecommunications is gaining attention as a potential turnaround story under new CEO Ken Traub, driven by recent strategic financing efforts, major contract wins in 911 services and satellite solutions, and active speculation regarding a high-value divestiture of its Terrestrial and Wireless segment. The community is also closely watching its emerging partnership with Quantum Computing Inc. for quantum satellite communications, poised to unlock substantial long-term value.

ACM Research, Inc. engages in the development, manufacture, and sale of single-wafer wet cleaning equipment. It supplies process solutions that semiconductor manufacturers can use in numerous manufacturing steps to remove particles, contaminants and other random defects, and thereby improve product yield. The company tools can be used in fabricating foundry, logic and memory chips including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company was founded by David H. Wang and Hui Wang in January 1998 and is headquartered in Fremont, CA.

ACM Research Inc - Ordinary Shares - Class A

ACM Research is trending following a bullish report from Kerrisdale Capital, which highlights the company's severe undervaluation compared to its Shanghai subsidiary and strong position in the growing semiconductor equipment market. The community is actively debating the stock's long-term potential fueled by expansion and robust fundamentals against persistent concerns over volatility and the impact of its significant China exposure.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is experiencing a strong rally following its significant beat on Q1 earnings and raised full-year guidance. This stellar performance is igniting community discussion around a potential short squeeze, given the company's high short interest and its position as an innovative AI-driven leader in the beauty-tech sector.

The New York Times Co. is a media organization, which engages in creating, collecting, and distributing news and information. It offers news products and other interest-specific products, and related content and services. It offers newspapers, print, and digital products and investments. The firm also manages The New York Times, NYTimes.com, and mobile applications. The company was founded by Henry Jarvis Raymond and George Jones on September 18, 1851, and is headquartered in New York, NY.

New York Times Co. - Ordinary Shares - Class A

The New York Times is trending as Berkshire Hathaway's new stake ignites community debate on the value of trusted content in the AI era, further fueled by the company's strong digital subscription growth and aggressive stance against AI firms for unauthorized content use.

Mondelez International, Inc. engages in the manufacture and marketing of snack food and beverage products. Its products include beverages, biscuits, chocolate, gum and candy, cheese and groceries, and meals. Its brands include 5Star, 7Days, Alpen Gold, Barni, Belvita, Bournvita, Cadbury, Cadbury Dairy Milk, Chips Ahoy! Clif, Clorets, Club Social, Côte d'Or, Daim, Enjoy Life Foods, Freia, Grenade, Halls, Honey Maid, Hu, Kinh Do, Lacta, Lu, Marabou, Maynards Bassett’s, Mikado, Milka, Oreo, Perfect Snacks, Philadelphia, Prince, Ritz, Royal, Sour Patch Kids, Stride, Tang, Tate’s Bake Shop, Tiger, Toblerone, Triscuit, TUC, and Wheat Thins. It operates through the following geographical segments: Latin America, Asia, Middle East, and Africa, Europe, and North America. The company was founded by James Lewis Kraft in 1903 is headquartered in Chicago, IL.

Mondelez International Inc. - Ordinary Shares - Class A

Mondelez is trending after exceeding recent earnings estimates, as investors debate whether muted 2026 guidance will overshadow the anticipated boost to future margins from dramatically falling cocoa prices, amidst ongoing discussions about consumer behavior and production strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Persistent Asset Partners Ltd Sells 71,539 Shares of TG Therapeutics, Inc. $TGTX

Persistent Asset Partners Ltd cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 83.6% in the third quarter, according to the company in its most recent disclosure with the SEC...

TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 14.5% during the 3rd quarter, according to its most recent 13F filing with the...

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat reports...

TG Therapeutics (NASDAQ:TGTX) Downgraded by Wall Street Zen to "Hold"

Wall Street Zen cut TG Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>TG Therapeutics launched the NextInMS platform to support people living with multiple sclerosis.</li><li>Briumvi remains the key growth driver, with the company guiding to $825 million to $850 million in global revenue from the drug in 2026.</li><li>Wall Street sees upside, with JPMorgan and Goldman Sachs pointing to roughly 59% and 35% upside, respectively, from the stock’s last close.</li></ul>TG Therapeutics, Inc. sparked heightened retail chatter on Monday after unveiling a new multiple sclerosis (MS) awareness collaboration with Christina Applegate, which debuted during Super Bowl LX.<h2 class="st-heading-2">TG Launches NextInMS Platform</h2>The company launched NextInMS.com, a new platform designed to encourage open and informed conversations among people living with MS, caregivers, and healthcare professionals.Applegate, who has been living with MS for five years, is leading the campaign and will share personal perspectives on navigating the disease and making long-term decisions. TG Therapeutics said the platform will also feature educational content from MS experts.<h2 class="st-heading-2">Briumvi Fuels 2026 Growth Outlook</h2>The campaign comes as TG Therapeutics continues to build momentum around Briumvi, its approved treatment for relapsing forms of multiple sclerosis. The company reported preliminary full-year 2025 global revenue of about $616 million, driven largely by Briumvi, which generated $594 million in U.S. net product revenue. Fourth-quarter U.S. net product revenue was estimated at roughly $182 million.The company also guided to a full-year 2026 total global revenue of $875 million to $900 million, including $825 million to $850 million in U.S. net product revenue from Briumvi. The company said it expects growth to be supported by ongoing commercial execution and efforts to further improve treatment convenience.Last year, TG Therapeutics completed enrollment in the Phase 3 Enhance trial evaluating a simplified intravenous dosing schedule for Briumvi, with topline data expected in mid-2026. The company also plans to announce pivotal topline data for a self-administered subcutaneous formulation around year-end 2026 or early 2027, alongside additional exploratory studies that could expand Briumvi’s use beyond multiple sclerosis.TG Therapeutics' six-year results showed that nearly 90% of patients on continuous Briumvi treatment remained free from disability progression, with a low annualized relapse rate and no new safety signals reported over extended follow-up.<h2 class="st-heading-2">Wall Street Sees Upside In TGTX Stock</h2>Earlier this month, JPMorgan lowered its price target on TG Therapeutics to $46 from $49, implying a 59% upside from the stock’s last close, while maintaining an ‘Overweight’ rating.&nbsp;On the other hand, Goldman Sachs raised its price target to $39 from $37, implying a 35% upside from current levels, and reiterated a ‘Neutral’ rating. The brokerage pointed to the company’s 2026 revenue guidance and progress in the Briumvi program.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TGTX was ‘bullish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tgtx_ss_png_fa811bf158.webp" alt="tgtx ss.png" width="972" height="139"><figcaption>TGTX sentiment and message volume as of February 9 | Source: Stocktwits</figcaption></figure>One user said, “TG actually partnered with Christina Applegate. She brings her authentic lived experience, it will expand brand visibility more than ever, build MORE trust with patients and providers, and will support B organically. Huge win for TG. If MW wanted to, its an easy sale from here..”<stembedurl>https://stocktwits.com/Insidersknow/message/644419693</stembedurl>Another user speculated that greater visibility around Christina Applegate’s treatment experience with TG Therapeutics could further boost the stock, saying, “TG rockets with even more impressive sales.”<stembedurl>https://stocktwits.com/PotionX1900/message/644429350</stembedurl><a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> has declined 14% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Christina Applegate (L) speaks onstage during the Light Up The Blues 7 Concert celebrating Autism Speaks' 20th Anniversary at the Greek Theatre on April 26, 2025 in Los Angeles, California. (Photo by Kevin Winter/Getty Images)

TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'

TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.

Equity

Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX

Universal Beteiligungs und Servicegesellschaft mbH lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.1% during the third quarter, according to the company in...

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports...

Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their Q4 2025 earnings per share estimates for TG Therapeutics in a research report issued to clients and...

TG Therapeutics (NASDAQ:TGTX) Trading 7.5% Higher - Here's Why

TG Therapeutics (NASDAQ:TGTX) Stock Price Up 7.5% - Here's What Happened...

HC Wainwright Forecasts TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their FY2025 EPS estimates for TG Therapeutics in a research report issued to clients and investors on...

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TGTX News

TGTXTG Therapeutics Inc